FDA approves Victoza for children with type 2 diabetes

Among the top stories in endocrinology last week were the FDA approval of Victoza for children with type 2 diabetes and a study that found prebiotic supplement increased C-peptide levels in children with type 1 diabetes.Liraglutide powder

Other highlights included a study that determined the use of SGLT2 inhibitors, GLP-1 receptor agonists and DPP-IV inhibitors was not associated with an increased risk for fracture in adults with type 2 diabetes, findings that suggested adults with severe forms of diabetic kidney disease along with limb ischemia can benefit from delays in the need for amputation with autologous cell therapy and a study that found cardiovascular health can be negatively affected by the deterioration of functional chewing capacity in older adults.
The FDA announced the approval of liraglutide for treating children aged at least 10 years with type 2 diabetes.

Prebiotic supplement increases C-peptide levels in children with type 1 diabetes

Children with type 1 diabetes assigned to a daily prebiotic powder supplement for 3 months experienced a “significant preservation” in C-peptide levels compared with children assigned to placebo, as well as increased intestinal permeability, according to findings from a small randomized controlled trial.

No increased fracture risk with real-world use of antidiabetes therapies

In an analysis of real-world data, the use of SGLT2 inhibitors, GLP-1 receptor agonists and DPP-IV inhibitors was not associated with an increased risk for fracture in adults with type 2 diabetes, according to findings published in Osteoporosis International.
Adults with severe forms of diabetic kidney disease along with limb ischemia can benefit from autologous cell therapy compared with traditional treatments, according to findings published in Diabetic Medicine.